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ABSTRACT
Objectives: The aim of this study was to evaluate the frequency of metabolic syndrome (MetS) and its components in 
patients with unexplained recurrent pregnancy loss (RPL). 
Material and methods: A cross-sectional study was held including 115 patients with unexplained RPL who were referred 
to a tertiary center between December 2018 and December 2019. In the study, MetS was classified according to The 
National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) criteria on the basis of metabolic risk 
factors. Frequency of MetS in the patients with unexplained RPL was investigated. The relationship between miscarriage 
rate and metabolic risk factors was also evaluated. 
Results: According to our study the percentage of MetS in patients with unexplained RPL was 24.4%. When evaluated ac-
cording to different age groups, it was 18.4% in patients aged 20–29 years, and it was 27.8% in patients aged 30–39 years. At 
least having one of its components were high (82.6%) in all patients with unexplained RPL. 
Conclusions: The percentage of MetS or of at least having one of its components were high in patients with unexplained 
RPL. Increased number of having MetS components were associated with increased miscarriage rate.
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INTRODUCTION 
Pregnancy loss is the most common complication of 
pregnancy, and RPL is defined as two or more failed clinical 
pregnancies as documented with histopathologic examina-
tion or ultrasonography [1]. This problem affects 1% to 5% of 
all couples trying to conceive [2]. Causes of RPL have been 
attributed to either endocrine, genetic, structural, immune, 
or infective factors. In addition to these factors, the causes 
of almost half of the cases remain unexplained [3]. MetS 
is a pandemic health problem that includes some clinical 
findings such as hyperglycemia, dyslipidemia, abdominal 
obesity, and hypertension which are metabolic risk factors 
for both cardiovascular disease and type 2 diabetes [4]. 
It has been shown that rare complications of pregnancy such 
as preeclampsia, and small for gestational age infancy are 
variously associated with the MetS [5]. Hyperglycemia and 
hypertension, which are components of the MetS, can af-
fect the vascular structure. Since the placenta is a vascular 
structure, any condition that may affect the vascular system 
may adversely affect the pregnancy outcomes. We suggest 
that MetS may be an etiological factor of unexplained RPL, 
hence we want to evaluate the frequency of MetS and its 
components in patients with RPL.
MATERIAL AND METHODS
This prospective cross-sectional study was conducted 
with a total of 115 patients with unexplained RPL who 
were referred to Harran University Hospital in Sanliurfa, 
Turkey, which is a tertiary referral center, between December 
2018 and December 2019. The study was approved by the 
Local Institutional Research Ethics Board. The characteristics 
of patients were shown in Table 1. Inclusion criteria were 
patients who lost two or more consecutive pregnancies 
before the 20th week of gestation with or without a previous 
live birth. All participants signed written informed consent 
prior to participating in the study. The clinical and obstetric 
history of participants was obtained. To investigate the eti-
ology of RPL, all women were examined with a transvaginal 
ultrasound to identify congenital uterine abnormalities and 
intrauterine pathologies, and where necessary for confir-
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mation, patients underwent a sonohysterography. Blood 
samples of participants were taken to determine possible 
endocrinological reasons for RPL, such as thyroid disorders, 
diabetes mellitus (DM), and hyperprolactinemia. Anticardi-
olipin Ig G and M, and levels of lupus anticoagulant were 
also evaluated to detect patients with Antiphospholipid 
Syndrome (APS). APS was diagnosed in accordance with 
the recommendations of international consensus criteria 
[6]. Maternal and paternal chromosome assessments were 
performed. In our clinic, these tests are routinely performed 
to clarify the etiology of RPL. The study was planned pros-
pectively in order to avoid any problems regarding recor-
ds of anthropometric measurements and tests. The study 
exclusion criteria included: Current pregnancy, smokers, 
alcohol consumption, maternal or paternal chromosome 
abnormalities, anatomical abnormalities, patients with APS, 
systemic diseases such as DM, hyperprolactinemia, thyroid 
dysfunction, chronic hypertension, systemic lupus erythe-
matosus. Height, weight, waist circumference and blood 
pressure (BP) were measured by trained medical personnel. 
Body mass index (BMI) was calculated by weight (kg) divi-
ded by the height (m²). After 5 minutes of rest, arterial BP 
was measured on the right upper arm by a semiautomatic 
oscillometric device. Fasting glucose, high-density lipopro-
tein, and triglycerides were evaluated from blood as part 
of a overall health assessment. MetS was diagnosed based 
on The NCEP ATP III as the presence of any three of the fol-
lowing five traits: 1) Abdominal obesity, defined as a waist 
circumference ≥ 102 cm (40 in) in men and ≥ 88 cm (35 in) 
in women. 2) Serum triglycerides ≥ 150 mg/dL (1.7 mmol/L) 
or drug treatment for elevated triglycerides. 3) Serum 
HDL-C < 40 mg/dL (1 mmol/L) in men and < 50 mg/dL 
(1.3 mmol/L) in women or drug treatment for low HDL-C. 
4) BP ≥ 130/85 mmHg or drug treatment for elevated BP. 
5) Fasting glucose (FG) ≥ 100 mg/dL (5.6 mmol/L) or drug 
treatment for elevated blood glucose [7].
Statistical analysis
The Statistical Package for Social Sciences (SPSS 22.0; 
SPSS Inc., Chicago, IL) was used in all statistical analyses. Ap-
plication of the Levene’s test revealed that data distributions 
were normal. Results were expressed as means ± standard 
deviations. Pearson correlation was done. The mean values 
of the the groups were analyzed using Independent Sam-
ple T Test. The values were calculated at level of (p < 0.05) 
significance.
RESULTS 
Among the study group, the majority were in the age 
group of 30–39 years (54 patients, 47%), followed by 20– 
–29 years (49 patients, 42.6%), 40–49 years (9 patients, 7.8%) 
and the patients aged below than 20 years were minimum 
in number (3 patients, 2.6%). The percentage of the MetS 
diagnosed using the ATP III criteria was 24.4% (28 of 115). 
The age adjusted percentage of MetS was calculated. It was 
18.4% in the age group of 20–29 years, and it was 27.8% in 
the age group of 30–39 years. There were 3 patients aged 
below 20 years, MetS was not seen in this group. There were 
9 patients in the age group of 40–49 years. MetS was seen in 
four of them. Because of the low number, percentages were 
not calculated. There was a negative correlation between 
HDL-C levels and miscarriage rate (r = –0.295, p < 0.01). Hy-
perglycemia and age were also associated with miscarriage 
rate (r = 0.277, p < 0.01; r = 0.272, p < 0.01 respectively). Addi-
tionally, an association had been seen between the presence 
of increased number of metabolic risk factors and miscar-
riage rate (r = 0.239, p < 0.05). We found that 27.8%, 30.4%, 
and 24.4% of the patients had at least 1, 2, or ≥ 3 metabolic 
risk factors, respectively. At least one metabolic risk factor 
was seen in 82.6% of patients. The frequency of individual 
components of the MetS in patients with RPL are presented 
in Table 2. Low HDL-C and abdominal obesity were the most 
frequent components of the MetS in patients with RPL. Fur-
thermore, patients were divided into two groups according 
to whether they had each metabolic risk factor or not, and 
evaluated in terms of miscarriage rate (Tab. 3). Low HDL-C 
group was associated with the increased miscarriage rate. 
It was statistically significant. 
DISCUSSION 
In this study we evaluated the percentage of MetS un-
der the ATP III definition in the group of patients with un-
explained RPL. We observed that the percentage of MetS 
or of at least having one of its components were high in 
these patients. Kozan et al. [8] studied the prevalence of 
the MetS in the adult Turkish population and they found 
that the prevalence was 9.6% in women aged 20–29 years, 
and 29.7 % in women aged 30–39 years. Soysal et al. [9] also 
studied the prevalence of MetS and its components among 
Table 1. Characteristics of patients recruited for the study
Mean Min–Max
Age [years] 30.30 ± 6.64 18–45
Gravidy 5.35 ± 2.41 2–13
Miscarriage rate 3.28 ± 1.39 2–8
Systolic blood pressure [mm Hg] 117.89 ± 10.02 100–170
Diastolic blood pressure [mm Hg] 74.76 ± 7.22 55–90
Body mass index [kg/m²] 26.28 ± 4.25 19–42
Waist circumference [cm] 83.14 ± 13.63 56–120
HDL- cholesterol [mg/dL] 50.03 ± 12.89 30–88
Triglyceride [mg/dL] 129.97 ± 75.99 41–452
Fasting glucose [mg/dL] 93.86 ± 10.93 75–125
Data were presented as mean ± standart deviation
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the young adults. They observed that the prevalence of 
MetS was 7.5% among 20 and 29 years old women and 24% 
among 30 and 39 years old women. It is known that MetS is 
more common in 30–39 years old people than in 20–29 years 
old people. Therefore, it is important to take notice that the 
percentage of MetS was 18.4% in 20–29 years old group in 
our study. Withal, according to our knowledge this is the 
first study to evaluate the percentage of MetS in patients 
with unexplained RPL.
Our study also examined the relationship between each 
component of MetS and the miscarriage rate. The increased 
miscarriage rate was statistically significant in patients with 
low HDL-C. Kozan et al. [8]  reported the most prevalent 
component of the MetS was abdominal obesity in women 
of Turkish adults, but we observed that low HDL-C was 
the most common component in our study. The percent-
age of low HDL-C was 92.86% (26/28) in the patients with 
MetS with RPL, and it was 58.26% (67/115) in the whole 
group. As outlined previously, within the whole group there 
were 3 patients aged below 20 years. Although their ages 
were below 20 years, two of them had two metabolic risk 
factors. The first patient had abdominal obesity and low 
HDL-C. The other one had hyperglycemia and low HDL-C. 
The common metabolic risk factor was low HDL-C. It is im-
portant to remember that low HDL-C is associated with 
vascular endothelial dysfunction [10]. Although the number 
of patients is statistically insignificant, we suggest that low 
HDL-C may predict the early onset of events affecting the 
vascular structure, therefore it may be an early sign of poor 
pregnancy outcomes including unexplained RPL.
In the literature, there are studies about the MetS and 
adverse pregnancy outcomes, Hooijschuur et al. [5] sug-
gested that different clinical manifestations of placental 
syndromes such as preeclampsia and small for gestational 
age infancy are variously associated with MetS. Murphy 
et al. [11] reported that risk ratios and prevalence rates 
for MetS increased in preeclamptic women at 1 year and 
3 years after birth. All components of MetS are associated 
with oxidative stress, inflammation, and endothelial dys-
function [12], withal 82.6% of patients in our study have 
one or more metabolic risk factors. Fortunately, endothelial 
dysfunction is reversible, and treating metabolic risk factors 
such as hypercholesterolemia and hypertension results in 
improved endothelial function resulting in restoration of 
vascular function. New guidelines lower the definition of 
high blood pressure, and it is accepted as ≥ 130/80 mmHg, 
in order to prevent negative outcomes of hypertension [13]. 
Therefore, regulating the tension below 130/80 mmHg may 
be appropriate for patients with unexplained RPL. 
Pregnancy is a procoagulant state, and MetS is as-
sociated with idiopathic venous thromboembolism [14], 
therefore patients with MetS are at high risk of developing 
thromboembolic disorders during pregnancy [15]. In cases 
of MetS, anticoagulant therapy from the time of conception 
may have beneficial effects in these patients. Published 
data specific to the use of anticoagulant agents in preg-
nant patients with MetS are needed. MetS is also associated 
with higher proinflammatory mediators, and heparin has 
a variety of antiinflammatory potentials. Therefore, some 
pregnancy complications including unexplained RPL may 
benefit from anticoagulant therapy such as heparinoids [16]. 
Although the anticoagulant therapy is not recommended 
in patients with unexplained RPL [17, 18], we suggest that 
using anticoagulant therapy may be useful because of high 
percentage of MetS in these patients, both for treatment 
and prevention of thromboembolic disorders. Evaluation of 
these patients only through the window of obstetrics may 
be insufficient, so a multidisciplinary team approach may be 
Table 3. The  effects of presence of each metabolic risk factors on 
miscarriage rate
Misscariage Rate p*
HDL Cholesterol < 50 mg/dL≥ 50 mg/dL
3.59 ± 1.51
2.83 ± 1.06 < 0.01
Triglyceride ≥ 150 mg/dL< 150 mg/dL
3.17 ± 1.45
3.32 ± 1.47 > 0.05
Fasting Glucose ≥ 100 mg/dL< 100 mg/dL
3.64 ± 1.68
3.16 ± 1.27 > 0.05
Abdominal 
Obesity
≥ 88 cm
< 88 cm
3.55 ± 1.55
3.06 ± 1.21 > 0.05
High Blood 
Pressure
≥ 130/85 mmHg
< 130/85 mmHg
2.80 ± 0.94
3.35 ± 1.43 > 0.05
Data were presented as mean ± standart deviation 
*Independent Samples T Test
Table 2. Frequency of individual components of the MetS in patients 
with RPL
All RPL Patients 
Frequency Percentage
Hyperglycemia 28/115 24.35 
Hypertriglyceridemia 30/115 26.09
Abdominal obesity (Waist 
circumference ≥ 88 cm) 51/115 44.35
Low HDL cholesterol 67/115 58.26
High blood pressure 15/115 13.04
RPL Patients with MetS
Frequency Percentage
Hyperglycemia 17/28 60.71
Hypertriglyceridemia 19/28 67.86
Abdominal obesity 23/28 82.14
Low HDL cholesterol 26/28 92.86
High blood pressure 5/28 17.86
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suitable. Healthier lifestyle changes, treating hypercholes-
terolemia, treating hypertension according to ACC/AHA [13], 
and anticoagulant therapy may be appropriate for patients 
with unexplained RPL. This study has some limitations. 
It has a cross sectional design, and the sample size of the 
study is low and data were obtained from a single center. 
Multi-center studies with more patients may be useful to 
advance this area of research.
In conclusion, this study may be significant for many rea-
sons. First, MetS and related conditions may play a role in the 
etiology of unexplained RPL, therefore treating metabolic 
risk factors may benefit pregnancy outcomes. Secondly, 
it may be possible to raise awareness of these patients in 
terms of early cardiovascular risk factors that may occur in 
the future, thus preventing future complications.
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